Gilead Sciences, Inc. (GILD)
151.17
+4.07
(+2.77%)
USD |
NASDAQ |
Oct 09, 16:00
151.13
-0.04
(-0.03%)
After-Hours: 20:00
Gilead Sciences Free Cash Flow (Quarterly) : 3.433B for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.433B |
| March 31, 2026 | 2.427B |
| December 31, 2025 | 3.122B |
| September 30, 2025 | 3.961B |
| June 30, 2025 | 720.00M |
| March 31, 2025 | 1.653B |
| December 31, 2024 | 2.828B |
| September 30, 2024 | 4.168B |
| June 30, 2024 | 1.195B |
| March 31, 2024 | 2.114B |
| December 31, 2023 | 1.954B |
| September 30, 2023 | 1.633B |
| June 30, 2023 | 2.198B |
| March 31, 2023 | 1.636B |
| December 31, 2022 | 2.386B |
| September 30, 2022 | 2.706B |
| June 30, 2022 | 1.659B |
| March 31, 2022 | 1.593B |
| December 31, 2021 | 3.049B |
| September 30, 2021 | 3.114B |
| June 30, 2021 | 2.197B |
| March 31, 2021 | 2.445B |
| December 31, 2020 | 1.735B |
| September 30, 2020 | 2.095B |
| June 30, 2020 | 2.423B |
| Date | Value |
|---|---|
| March 31, 2020 | 1.265B |
| December 31, 2019 | 2.377B |
| September 30, 2019 | 2.699B |
| June 30, 2019 | 2.036B |
| March 31, 2019 | 1.207B |
| December 31, 2018 | 2.097B |
| September 30, 2018 | 2.045B |
| June 30, 2018 | 1.276B |
| March 31, 2018 | 2.058B |
| December 31, 2017 | 2.533B |
| September 30, 2017 | 2.565B |
| June 30, 2017 | 3.403B |
| March 31, 2017 | 2.807B |
| December 31, 2016 | 3.695B |
| September 30, 2016 | 4.132B |
| June 30, 2016 | 4.519B |
| March 31, 2016 | 3.953B |
| December 31, 2015 | 4.708B |
| September 30, 2015 | 3.81B |
| June 30, 2015 | 5.487B |
| March 31, 2015 | 5.577B |
| December 31, 2014 | 2.853B |
| September 30, 2014 | 3.909B |
| June 30, 2014 | 4.094B |
| March 31, 2014 | 1.405B |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| AbbVie, Inc. | 3.114B |
| Amgen, Inc. | 3.489B |
| Vertex Pharmaceuticals, Inc. | 1.013B |
| Biogen, Inc. | 308.00M |
| Regeneron Pharmaceuticals, Inc. | 521.80M |